Your browser doesn't support javascript.
In silico drug repurposing in COVID-19: A network-based analysis.
Sibilio, Pasquale; Bini, Simone; Fiscon, Giulia; Sponziello, Marialuisa; Conte, Federica; Pecce, Valeria; Durante, Cosimo; Paci, Paola; Falcone, Rosa; Norata, Giuseppe Danilo; Farina, Lorenzo; Verrienti, Antonella.
  • Sibilio P; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; Institute for Systems Analysis and Computer Science "Antonio Ruberti", National Research Council, Rome, Italy.
  • Bini S; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
  • Fiscon G; Institute for Systems Analysis and Computer Science "Antonio Ruberti", National Research Council, Rome, Italy; Fondazione per la Medicina Personalizzata, Via Goffredo Mameli, 3/1, Genova, Italy.
  • Sponziello M; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
  • Conte F; Institute for Systems Analysis and Computer Science "Antonio Ruberti", National Research Council, Rome, Italy.
  • Pecce V; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
  • Durante C; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
  • Paci P; Institute for Systems Analysis and Computer Science "Antonio Ruberti", National Research Council, Rome, Italy; Department of Computer, Control, and Management Engineering, Sapienza University of Rome, Rome, Italy. Electronic address: paci@diag.uniroma1.it.
  • Falcone R; Phase 1 Unit-Clinical Trial Center Gemelli University Hospital, Rome, Italy.
  • Norata GD; Department of Excellence in Pharmacological and Biomolecular Sciences, University of Milan and Center for the Study of Atherosclerosis, SISA Bassini Hospital, Milan, Italy.
  • Farina L; Department of Computer, Control, and Management Engineering, Sapienza University of Rome, Rome, Italy.
  • Verrienti A; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Biomed Pharmacother ; 142: 111954, 2021 Oct.
Article in English | MEDLINE | ID: covidwho-1330660
ABSTRACT
The SARS-CoV-2 pandemic is a worldwide public health emergency. Despite the beginning of a vaccination campaign, the search for new drugs to appropriately treat COVID-19 patients remains a priority. Drug repurposing represents a faster and cheaper method than de novo drug discovery. In this study, we examined three different network-based approaches to identify potentially repurposable drugs to treat COVID-19. We analyzed transcriptomic data from whole blood cells of patients with COVID-19 and 21 other related conditions, as compared with those of healthy subjects. In addition to conventionally used drugs (e.g., anticoagulants, antihistaminics, anti-TNFα antibodies, corticosteroids), unconventional candidate compounds, such as SCN5A inhibitors and drugs active in the central nervous system, were identified. Clinical judgment and validation through clinical trials are always mandatory before use of the identified drugs in a clinical setting.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Computer Simulation / Drug Repositioning / COVID-19 / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Biomed Pharmacother Year: 2021 Document Type: Article Affiliation country: J.biopha.2021.111954

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Computer Simulation / Drug Repositioning / COVID-19 / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Biomed Pharmacother Year: 2021 Document Type: Article Affiliation country: J.biopha.2021.111954